Phase 2
N=73
Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Bottom Line
View on ClinicalTrials.gov: NCT00217087 ↗Enrolled (actual)
73
Serious AEs
6.9%
Results posted
Sep 2015
Primary outcome: Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Endoscopic Mucosal Resection (Procedure); Photodynamic Therapy (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Level of Dysplasia on Histology at 12 Months |
10; 11; 15; 2 | 0.0098 sig |
| PRIMARY Fluorescence In Situ Hybridization (FISH) Markers at 12 Months. |
7; 8; 6; 5; 4; 5 | 0.34 |
| PRIMARY Change in Quality of Life |
9; 6; 1; 0 | 0.2 |
Summary
This study is being done to see if treatment for esophageal cancer can be done using endoscopy for patients ineligible for surgical or radiological therapy. The standard method of treating this type of cancer is surgical removal of the esophagus. The study will determine if removing just the cancer with endoscopy is enough treatment or if the addition of another treatment called photodynamic therapy (treatment with a red light and a drug called sodium porfimer) is needed.
Eligibility Criteria
Inclusion Criteria
- Non-recurrent adenocarcinoma in Barrett's Esophagus confirmed by two experienced gastrointestinal pathologists
- No evidence of submucosal invasion
- No evidence of metastatic disease in either regional or distal lymph nodes, or other organs
- Pre-entry CT scans of the upper abdomen and chest and Endoscopic Ultrasound (EUS) of the tumor and regional lymph nodes are required. Fusion PET scans are suggested for any indeterminate lesions
- Zubrod Performance Status 0-1
- Participants must be have oral intake of greater than 1700 calories a day
- Patient must not have had a second malignancy, other than curable non-melanoma skin cancer or cervical cancer in situ, unless disease free for greater than or equal to 3 years and deemed cured by their hematologist and/or oncologist
- Staging procedures should be performed prior to study entry
- All patients or legally authorized representative must sign a study-specific informed consent prior to randomization.
Exclusion criteria
- Prior major esophageal surgery
- Patients who are unable to tolerate endoscopic procedures
- Due to the possible toxic effects of photodynamic therapy and endoscopic sedation to embryos, pregnant or lactating women or men unable or unwilling to practice contraception are excluded
- Patients with an uncontrolled diabetes, heart disease, or hypertension
- Patient and/or legally authorized representative who are unable to comprehend the study requirements or who are not likely to comply with the study parameters.
Data sourced from ClinicalTrials.gov (NCT00217087). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.